Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00121147
Recruitment Status : Completed
First Posted : July 21, 2005
Last Update Posted : February 24, 2006
Alcon Research
Information provided by:
Hermann Eye Center

Brief Summary:
The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan.

Condition or disease Intervention/treatment Phase
Open Angle Glaucoma Ocular Hypertension Pseudoexfoliation Syndrome Drug: Travatan Drug: Azopt Drug: Alphagan P Not Applicable

Detailed Description:

The purpose of this research study is to compare the effect on the pressure inside the eye when Brinzolamide Ophthalmic Suspension, 1% (Azopt), a carbonic anhydrase inhibitor, and Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan-P), an alpha 2 agonist, are added to Travoprost Ophthalmic Solution, 0.004% (Travatan), a prostaglandin, in patients with primary open angle glaucoma, ocular hypertension and pseudoexfoliation syndrome. Brinzolamide Ophthalmic Suspension, 1% (Azopt), Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan-P), and Travoprost Ophthalmic Solution, 0.004% (Travatan) are all currently approved by the FDA and on the market, being used by patients. Even though all three medications are currently approved for the purpose of the study they will be considered study medicines.

Glaucoma, Ocular Hypertension and Pseudoexfoliation syndrome have been treated with IOP-lowering medications or surgery to lower the pressure inside the eye to reduce the risk of visual field loss. Today, common treatments for a patient often begins with the prescription of a prostaglandin (Travoprost). If the prostaglandin does not lower the pressure inside the eye enough, a second drug is usually added. Topical carbonic anhydrase inhibitors (Brinzolamide) and alpha 2 agonists (Brimonidine) are common choices as additive medicines.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Comparison of the Additivity of Brinzolamide Ophthalmic Suspension, 1% (Azopt) and Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan P) to Travoprost Ophthalmic Solution, 0.004% (Travatan) in Patients With Elevated IOP on Travoprost. A Three Month Double-Masked, Multi-Center Trial in the United States
Study Start Date : September 2003
Study Completion Date : October 2005

Primary Outcome Measures :
  1. Mean decrease in diurnal intraocular pressure (IOP) (mean of the three daily intraocular pressures) at month 3 visit

Secondary Outcome Measures :
  1. Change in IOP from baseline at each time point
  2. IOP at 8AM (prior to dosing), 12 noon and 4 pm at month 3
  3. Percent IOP lowering from pretreatment baseline to the three month visit. Both diurnal average and at each time point
  4. Percent of patients reaching specific target pressures after three months of treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 0 Years
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Minimum age: 35 years
  • Uni or bilateral primary open angle glaucoma, ocular hypertension or pseudoexfoliation syndrome (POAG is defined as having VF and optic nerve changes consistent with glaucomatous disease)
  • Insufficient response to monotherapy: defined as IOP > 18mm Hg (mean diurnal) and less than 32 mm Hg on Travatan at baseline
  • Informed consent and HIPPA consent obtained at screening visit prior to any study events
  • Ability to adhere to study treatment visit plan

Exclusion Criteria:

  • Closed, occluded, or potentially occludable angle
  • History of angle closure
  • Previous intraocular surgery, except uncomplicated clear cornea phacoemulsification or argon laser trabeculoplasty
  • Argon laser trabeculoplasty or phacoemulsification within the last 3 months
  • Central corneal thickness outside the 500 - 600 (inclusive) micron range as measured by ultrasonic pachymetry
  • Ocular or periocular inflammation within 3 months prior to study (except blepharitis related or seasonal allergic conjunctivitis)
  • History of uveitis or previous intraocular inflammation (other than post-operatively)
  • Hypersensitivity to sulfa, alpha agonists or benzalkonium chloride
  • History of use of any steroids for over 1 week within 3 months of screening or likely need for any corticosteroids during the study (except inhaled, nasal or topical non-ocular)
  • Use of systemic medications known to effect IOP (e.g. Alpha agonists, Beta blockers, Ace inhibitors and angiotensin II receptor blockers) which have not been stable for three months prior to baseline and the dosage is not expected to change during the course of the study


  • Pregnancy (study medications have been determined to cause possible harm to the fetus)
  • Women of childbearing potential who are not using contraceptive methods. Childbearing potential is defined as any woman who is not postmenopausal (12 months without a menstrual period) or surgically sterile. Contraceptive methods are defined as abstinence, having a vasectomized partner, or ongoing use of approved oral, injectable, topical or implanted contraceptives, a barrier method or an IUD


  • Use of any investigational medication within one month prior to baseline visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00121147

Show Show 21 study locations
Sponsors and Collaborators
Hermann Eye Center
Alcon Research
Layout table for investigator information
Study Chair: Robert M Feldman, M.D. Hermann Eye Fund / University of Texas
Layout table for additonal information Identifier: NCT00121147    
Other Study ID Numbers: HEF-042
First Posted: July 21, 2005    Key Record Dates
Last Update Posted: February 24, 2006
Last Verified: July 2005
Keywords provided by Hermann Eye Center:
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma, Open-Angle
Ocular Hypertension
Exfoliation Syndrome
Eye Diseases
Iris Diseases
Uveal Diseases
Brimonidine Tartrate
Antihypertensive Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs